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The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast
cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RNA was
extracted from 268 formalin-fixed paraffin-embedded (FFPE) tumour tissue samples of high-risk breast cancer patients enrolled in the
randomised HE10/97 trial, evaluating the effect of dose-dense anthracycline-based sequential adjuvant chemotherapy with or without
paclitaxel. The mRNA expression of all four HER family members was assessed by kinetic reverse transcription-polymerase chain
reaction (kRT–PCR). The overall concordance between kRT–PCR and IHC/FISH for HER2 status determination was 74%. At a
median follow-up of 8 years, multivariate analysis showed that EGFR and HER2 mRNA expression was associated with reduced
overall survival (OS). HER3 and HER4 mRNA level had a favourable prognostic value in terms of OS and disease-free survival (DFS),
respectively. Adjusting for HER2 mRNA expression, OS and DFS did not differ between treatment groups. These data indicate that
EGFR as well as HER2 are prognostic factors of worse clinical outcomes, whereas HER3 and HER4 gene transcription is associated
with better prognosis in high-risk early breast cancer. However, HER2 mRNA expression did not predict clinical benefit from
paclitaxel. Kinetic RT–PCR represents an alternative method for evaluating the expression of HER family members in FFPE breast
carcinomas.
British Journal of Cancer (2008) 99, 1775–1785. doi:10.1038/sj.bjc.6604769 www.bjcancer.com
Published online 4 November 2008
& 2008 Cancer Research UK
Keywords: HER family; mRNA; kRT-PCR; prognostic value; predictive value; breast cancer
                                                                  
Adjuvant chemotherapy improves disease-free survival (DFS) and
overall survival (OS) in early-stage breast cancer (EBCTCG, 2005)
with taxanes representing active agents in such a treatment.
However, chemotherapy is associated with potentially life-threa-
tening side effects. Therefore, the identification of reliable
prognostic factors as well as biological markers that might have
the ability to predict therapeutic response is crucial. So far, no
biomarkers have been identified that can reliably predict clinical
benefit from paclitaxel in breast cancer patients.
The human epidermal growth factor receptor (HER) family
comprises of four homologous members: ErbB-1 (epidermal
growth factor receptor (EGFR) or HER1), ErbB-2 (HER2) for
which no ligand has been described so far, ErbB-3 (HER3) which is
characterised by its impaired kinase activity, and ErbB-4 (HER4)
(Mosesson and Yarden, 2004). There is an extensive literature on
the role of the HER family in breast cancer and particularly that of
HER2, which is considered to be a key oncogene in breast
carcinogenesis. Overexpression or amplification of HER2 occurs in
15–30% of breast carcinomas and is considered to confer a more
aggressive biology and an unfavourable impact on the course of
the disease (Slamon et al, 1987). Moreover, it has been suggested
that HER2 overexpression or amplification in breast cancer
predicts greater sensitivity to anthracycline-containing chemother-
apy (Gennari et al, 2008) and resistance to the CMF regimen
(Gusterson et al, 1992). HER2 may also identify patients who are
likely to benefit from higher doses of adjuvant chemotherapy
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regarding the response to taxane-based chemotherapy is consid-
ered controversial and the results of the studies have been
conflicting, so far (Pritchard et al, 2008). Although some trials have
supported an interaction between HER2 overexpression and
taxane activity (Konecny et al, 2004; Hayes et al, 2007), others
have failed to demonstrate such an association (Gonzalez-Angulo
et al, 2004). Only a limited number of studies have evaluated the
effect of taxane-containing regimens with respect to HER2 status
in the adjuvant setting (Martin et al, 2005; Kostopoulos et al, 2006;
Hayes et al, 2007).
In the light of clinical data suggesting that HER2 can be useful as
a predictive marker for both trastuzumab and chemotherapy,
standardised determination of the HER2 status in tumours has
become more important. HER2 can be analysed at the DNA, the
mRNA or the protein level. Various techniques are available, each
with advantages and disadvantages. For practical reasons,
immunohistochemistry (IHC) using an anti-HER2 antibody is
currently the method of choice for HER2 testing. However, major
drawbacks of IHC are that the results are not quantitative, the
interpretation is significantly influenced by several technical
factors and the inter-observer variation is quite large. Although
these discrepancies are improved by the use of standardised IHC
tests (such as the HercepTest), it is generally recommended that
(2þ) HER2 immunostaining needs to be further validated by
fluorescence in situ hybridisation (FISH) analysis (Ellis et al, 2000;
Mass et al, 2000; Birner et al, 2001; Bartlett et al, 2003). Despite
efforts to standardise these assays, substantial intra- and inter-
laboratory variability of the results still exist. Kinetic reverse
transcription–polymerase chain reaction (kRT–PCR) has recently
been suggested as an alternative technique for the detection and
quantification of HER2 expression. kRT–PCR is simple, relatively
fast and produces reliable, quantitative and reproducible results.
Moreover, it can easily be standardised, reduces inter-observer
variability and does not require experienced pathologists for
interpretation. However, a disadvantage of this technique is the
specific requirements for handling of the tissue specimens to
preserve the integrity of RNA. Recent studies have shown that the
small amounts of degraded RNA in archival formalin-fixed
paraffin-embedded (FFPE) tissues can be successfully amplified
and detected using kRT–PCR techniques (Gjerdrum et al, 2004).
EGFR is overexpressed in several human tumours and is
considered to initiate a variety of important steps during the
malignant transformation. It has been estimated that 45% of
human breast carcinomas overexpress EGFR (range, 14–91%)
(Klijn et al, 1992). So far, there are no widely accepted criteria for
the determination of EGFR status. EGFR overexpression has been
associated with oestrogen receptor (ER) and progesterone receptor
(PR) negativity (Pawlowski et al, 2000; Ferrero et al, 2001; Tsutsui
et al, 2002; Bieche et al, 2003). Moreover, there may be an
association between EGFR positivity and high histological grade or
lymph node involvement, although not all existing studies are in
agreement (Pawlowski et al, 2000; Ferrero et al, 2001; Witton et al,
2003; Rampaul et al, 2004; Tzaida et al, 2007). Currently, the
prognostic significance of EGFR in breast cancer patients remains
unclear. In addition, HER3 overexpression has been documented
in 20–30% of invasive breast carcinomas. The prognostic
significance of HER3 expression is also poorly documented and
the available data are conflicting (Quinn et al, 1994; Travis et al,
1996; Pawlowski et al, 2000). With respect to the HER4 receptor,
the current evidence suggests that it is characterised by
antiproliferative activity (Naresh et al, 2006). HER4 overexpression
has been reported as a favourable prognostic factor in the
literature (Pawlowski et al, 2000; Suo et al, 2002; Witton et al,
2003). The HER family represents therefore an attractive area for
the application of targeted therapies in breast cancer and
significant treatment advances have been made, so far. As trans-
signalling is now considered an essential feature of HER family
function, the role of lateral signalling partners is also becoming
increasingly important.
In this study, we assessed the prognostic significance of HER
family mRNA expression using kRT–PCR, in a series of high-risk
early breast cancer patients, treated with dose-dense anthracy-
cline-based sequential adjuvant chemotherapy with or without
paclitaxel, within the context of a randomised phase III clinical
trial. Furthermore, we investigated whether HER family mRNA
expression in the tumour could possibly identify patients who are
likely to benefit from the addition of paclitaxel to adjuvant
chemotherapy.
MATERIALS AND METHODS
Patients
Formalin-fixed paraffin-embedded tissue blocks of primary breast
cancer were retrospectively collected from 268 patients who were
part of the Hellenic Cooperative Oncology Group (HeCOG) 10/97
trial population. The basic patient and tumour characteristics are
shown in Table 1. The HE10/97 trial randomised a total of 595
high-risk (T1-3N1M0 or T3N0M0) breast cancer patients in the
period 1997–2000, to receive either 4 cycles of epirubicin (E)
followed by 4 cycles of intensified CMF (cyclophosphamide,
methotrexate and 5-fluorouracil) combination chemotherapy
(E-CMF) or 3 cycles of epirubicin followed by 3 cycles of paclitaxel
(T) and 3 cycles of intensified CMF (E-T-CMF). Chemotherapy
cycles were administered every 2 weeks and patients received
granulocyte-colony stimulating factor (G-CSF) support. The trial
was approved from the Bioethics Committee of the Aristotle
University of Thessaloniki and patients provided written informed
consent prior to enrolment. All participating patients also gave
written informed consent for research use of their biologic
material. The results of the HE10/97 study have been recently
reported (Fountzilas et al, 2005).
Pathologic determinations
Primary tumour diameter and axillary nodal status were obtained
from the histopathological report. ER and PR status was assessed
by IHC, whereas relative information was provided by the
participating institutions according to their own reference
laboratories. Tissue paraffin sections stained for ER/PR were
considered as positive even when only a small number of
neoplastic cells displayed nuclear immunoreactivity. Histological
grade was evaluated according to the Scarff, Bloom and
Richardson system.
Molecular and immunohistochemical studies
Owing to the logistical and organisational barriers arising from the
retrospective nature of the study, collection of FFPE tumour tissue
samples was possible in less than half of the patients enrolled in
the HE10/97 prospective clinical trial. RNA was isolated from 268
FFPE tumour tissue samples employing an experimental method
based on proprietary magnetic beads from Siemens Healthcare
Diagnostics (Cologne, Germany). For all tumour samples included
in the analysis the number of malignant cells represented at least
75% of all nucleated cells per section, as verified by haematoxylin–
eosin staining. Kinetic RT–PCR was applied for the assessment of
the expression of the EGFR, HER2, HER3, and HER4 genes using
gene-specific TaqMant-based primer/probe sets. Forty cycles of
nucleic acid amplification were applied and the cycle threshold
(Ct) values of the target genes were identified. Ct values were
normalised by subtracting the Ct value of the housekeeping gene
RPL37A from the Ct value of the target gene (DCt). RNA results
were then reported as 40-DCt values, which would correlate
proportionally to the mRNA expression level of the target gene.
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xylol and ethanol, the pellet was washed with ethanol and dried at
551C for 10min. The pellet was then lysed and proteinised
overnight at 551C with shaking. After addition of a binding buffer
and the magnetic particles (Siemens Healthcare Diagnostics,
Cologne, Germany) nucleic acids were allowed to bind to the
particles for 15min at room temperature. On a magnetic stand, the
supernatant was aspirated and the beads were washed several
times with a washing buffer. After addition of an elution buffer and
incubation for 10min at 701C, the supernatant was aspirated on a
magnetic stand without touching the beads. After normal DNAse I
treatment for 30min at 371C and inactivation of DNAse I the RNA
Table 1 Basic patient and tumour characteristics
All patients N¼268 E-T-CMF N¼117 E-CMF N¼151
Age (years)
Median (range) 51 (22–76) 52 (28–76) 51 (22–76)
Number of nodes removed
Median (range) 20 (4–59) 21 (5–59) 20 (4–53)
Number of positive nodes
Median (range) 6 (0–54) 7 (0–54) 6 (0–49)
N (%) N (%) N (%)
Positive nodes categories
0 nodes 3 (1) 2 (2) 1 (1)
1–3 nodes 58 (22) 22 (19) 36 (24)
4–9 nodes 122 (46) 57 (49) 65 (43)
49 nodes 85 (32) 36 (31) 49 (32)
Menopausal status
Premenopausal 136 (51) 55 (47) 81 (54)
Postmenopausal 132 (49) 62 (53) 70 (46)
Type of operation
Modified radical mastectomy 215 (80) 95 (81) 120 (79)
Breast-conserving surgery 53 (20) 22 (19) 31 (21)
Interval from operation
o2 weeks 42 (16) 16 (14) 26 (17)
2–4 weeks 126 (47) 64 (55) 62 (41)
44 weeks 100 (37) 37 (32) 63 (42)
Tumour size
p2cm 81 (30) 34 (29) 47 (31)
2–5cm 136 (51) 62 (53) 74 (49)
45cm 51 (19) 21 (18) 30 (20)
Histology
Invasive ductal 190 (71) 85 (73) 105 (70)
Invasive lobular 33 (12) 13 (11) 20 (13)
Mixed 30 (11) 12 (10) 18 (12)
Other 10 (4) 4 (3) 6 (4)
Unspecified 2 (1) 1 (1) 1 (1)
Unknown 3 (1) 2 (2) 1 (1)
Grade
I–II 135 (50) 48 (41) 87 (58)
III-Undifferentiated 132 (49) 68 (58) 64 (42)
Unknown 1 (0.4) 1 (1) 0 (0)
ER/PR status (IHC)
Negative 58 (22) 26 (22) 32 (21)
Positive 206 (77) 89 (76) 117 (77)
Unknown 4 (1) 2 (2) 2 (1)
HER2 overexpression (IHC)
No 164 (61) 64 (55) 100 (66)
Yes 64 (24) 30 (26) 34 (23)
Unknown 40 (15) 23 (20) 17 (11)
EGFR overexpression (IHC)
No 201 (75) 95 (81) 106 (70)
Yes 40 (15) 15 (13) 25 (17)
Unknown 27 (10) 7 (6) 20 (13)
Patient characteristics are well balanced between the two arms, with the exception of grade (P¼0.010), a difference also observed in the prospective clinical trial.
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260 and 280nm. RNA was then used in RT–PCR. The primer/
probe sets used for amplification of the target genes were the
following:
EGFR Probe CCTTGCCGCAAAGTGTGTAACGGAAT
Forward Primer CGCAAGTGTAAGAAGTGCGAA
Reverse Primer CGTAGCATTTATGGAGAGTGAGTCT
HER2 Probe ACCAGGACCCACCAGAGCGGG
Forward Primer CCAGCCTTCGACAACCTCTATT
Reverse Primer TGCCGTAGGTGTCCCTTTG
HER3 Probe CTCAAAGGTACTCCCTCCTCCCGGG
Forward Primer CGGTTATGTCATGCCAGATACAC
Reverse Primer GAACTGAGACCCACTGAAGAAAGG
HER4 Probe CACAGACTGCTTTGCCTGCATGAATTTC
Forward Primer GAGGCTGCTCAGGACCTAAGG
Reverse Primer GAGTAACACATGCTCCACTGTCATT
Human reference total RNA pooled from 10 human cell lines
(Stratagene, La Jolla, California, USA) was used as a positive
control. RNA-free DNA extracted from tumour tissues was used as
a negative control.
Data regarding EGFR and HER2 protein expression using IHC
were available in 241 and 228 patients, respectively (Table 1).
EGFR was assessed at the Department of Pathology of the Metaxas
Cancer Hospital, Athens, as described earlier (Tzaida et al, 2007).
HER2 was determined at the Department of Pathology of the
Hygeia Hospital, Athens, with additional analysis of cases with an
IHC score of 2þ by FISH, as described earlier (Kostopoulos et al,
2006).
Statistical analysis
Categorical data are presented as counts and corresponding
percentages, whereas continuous data are presented as medians
and ranges. For all receptors, the median was the pre-specified
cutoff point and its distinguishing ability for patient prognosis was
tested by means of the log-rank test. In case of no distinguishing
ability of the median in terms of OS, the plan was to proceed
with an exploratory analysis to test if the 25th and 75th percentiles
were more appropriate cutoffs. Exploratory analysis was per-
formed in a subgroup of the sample and validated in the rest of
the patients. If the 25th and 75th percentiles were not validated as
appropriate cutoff points, exploration would continue from the
10th to the 90th percentiles. In case a conclusion was reached on a
cutoff point through exploration, subsequent analysis would
initially be performed excluding the corresponding gene and
repeated including it at the optimal cutoff (ability to distinguish
OS significantly in the whole sample). We present the results of
the analysis including this gene, only in cases where the results
were not altered significantly. Comparison of categorical data
between groups of patients was performed using the w
2-test.
Variables included in the comparisons were involved lymph nodes
(0–3 vs X4), histological grade (good or moderate vs poor or
undifferentiated), ER and PR status (positive vs negative), tumour
size (p2 vs 2–5 vs 45cm), histology (ductal vs lobular vs
other) and age (o50 vs 450 years). Continuous data were
compared using the Mann–Whitney test, or the Kruskal–Wallis
test in case of more than two groups. Correlations among the
receptors were assessed using the Spearman’s Correlation Coeffi-
cient Method.
Overall survival was measured from time of chemotherapy
initiation to patient’s last contact or death. Disease-free survival
was measured from time of chemotherapy initiation to patient’s
last contact or disease progression. Cases of disease progression,
deaths from any cause without verified relapse and second cancers
were treated as events in the estimation of DFS (Hudis et al, 2007).
Survival was estimated using the Kaplan–Meier method. Compar-
isons between groups of patients, as defined by receptor cutoffs,
were performed using the log-rank test. Multivariate Cox analysis
including age (o50 vs 450 years), involved lymph nodes (0–3 vs
X4), histology (ductal vs lobular vs other), histological grade
(good or moderate vs poor or undifferentiated), size (p2 vs 2–5vs
45cm), ER/PR status (positive vs negative), hormonotherapy (yes
vs no), radiotherapy (yes vs no), EGFR (X75th percentile vs o75th
percentile), and HER2, HER3, HER4 (Xmedian vs omedian) was
performed. Variable selection was performed based on the
likelihood ratio test with an exclusion criterion set at 0.10. The
final model was adjusted for the group of randomisation
(E-T-CMF vs E-CMF). Interaction between paclitaxel containing
chemotherapy and the genes of interest was also considered. Level
of significance was a¼0.05 for all tests. Results of this study were
presented according to reporting recommendations for tumour
marker prognostic studies (McShane et al, 2005). The statistical
analysis was conducted using SPSS 11 for Windows.
RESULTS
Normalised mRNA expression of HER family receptors
The distribution of tumour samples according to the normalised
expression of mRNA encoding for HER family receptors is shown
in Figure 1. The median value for EGFR was 32.95 (range, 24.85–
36.11), for HER2 35.56 (range, 30.32–40.98), for HER3 34.63
(range, 28.3–37.1), and for HER4 31.79 (range, 24.67–35.43).
Concordance between kinetic RT–PCR and IHC
The total number of tumours with data available from both IHC
and kRT–PCR was 240 and 228 for EGFR and HER2, respectively.
For EGFR, 39 of the 240 tumours (16%) were IHC positive, whereas
59 tumours (24.5%) were kRT–PCR positive. For HER2, 64 of the
228 tumours (28%) were IHC/FISH positive, whereas 113 tumours
(49.5%) had HER2 mRNA expression above the median, as
assessed by kRT–PCR. For these tumours, we found a statistically
significant association between the evaluations obtained by the two
methods, for the EGFR (Mann–Whitney test, Po0.001) and the
HER2 (Kruskal–Wallis test, Po0.001) receptors. The observed
overall concordance between the determination of HER2 by kRT–
PCR and IHC/FISH was 74%. The levels for sensitivity and
specificity were 92 and 67%, respectively. The overall agreement
between kRT–PCR and IHC for EGFR was 75%. Sensitivity and
specificity were 49 and 80%, respectively (Table 2).
Relationships among HER family receptors mRNA
expression
A positive correlation was found between HER2 and HER3 mRNA
levels (r¼0.224, Po0.001). No association was demonstrated
between HER2 and the other two family members. Moreover,
HER3 and HER4 mRNA values were positively correlated to each
other (r¼0.444, Po0.001) and negatively correlated to EGFR
(r¼ 0.143, P¼0.019 and r¼ 0.125, P¼0.043, respectively).
Association of HER family receptors mRNA expression
with clinicopathological parameters
EGFR mRNA expression was inversely related to the presence of
ER (P¼0.044). HER2 was positively associated with the number of
involved lymph nodes (P¼0.013). HER3 mRNA expression was
associated with ER positivity (P¼0.017), whereas HER4 was
associated with histopathological grade IþII (P¼0.001) and ER
and PR positivity (Po0.001 and Po0.001, respectively). Further-
more, EGFR mRNA expression was inversely associated with
ductal histology (P¼0.029), whereas that of HER2 was positively
associated with ductal histological type (P¼0.001).
Prognostic value of HER family mRNA in early breast cancer
AK Koutras et al
1778
British Journal of Cancer (2008) 99(11), 1775–1785 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sPrognostic value of HER family receptors mRNA
expression
Survival status of the patients was updated in October 2007. The
median follow-up time was 95.5 months (95% CI: 92.4–98.6, range,
7–117 months). During this time, 87 patients had developed a
relapse and 61 patients had died. The 3-year OS was 93% (95% CI:
90–96%), whereas the 5-year OS was 85% (95% CI: 81–90%). The
3-year DFS was 80% (95% CI: 75–84%), whereas the 5-year DFS
was 74% (95% CI: 68–79%).
For each of the HER family receptors, three cutoff points (25th,
50th and 75th percentiles) were assessed for prognostic value. In
the majority of cases, the median (50th percentile) was the optimal
cutoff point. However, in the case of EGFR the 75th percentile was
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Figure 1 Distribution of breast carcinoma specimens according to normalised expression of mRNA encoding for HER family receptors.
Table 2 Evaluation of HER2 and EGFR by kRT–PCR compared with IHC
HER2 (IHC/FISH) N¼228
0, 1+, 2+/FISH( ) 2+/FISH(+), 3+ NPV/PPV % Sensitivity % Specificity %
HER2 (kRT-PCR)
Below median 110 (67%) 5 (8%) 96/52 92 67
Above median 54 (33%) 59 (92%)
EGFR (IHC) N¼240
Negative Positive
EGFR (kRT–PCR)
Below 75th percentile 161 (80%) 20 (51%) 89/32 49 80
Above 75th percentile 40 (20%) 19 (49%)
NPV, negative predictive value; PPV, positive predictive value.
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sthe best threshold, allowing us to distinguish two populations of
significantly different prognosis. Using the 75th percentile,
patients whose tumours had increased EGFR mRNA expression
had significantly reduced OS (22 out of 67 deaths in EGFR-positive
vs 38 out of 200 deaths in EGFR-negative patients, log-rank
P¼0.022) (Figure 2A1). The hazard ratio (HR) for death in EGFR-
positive patients was 1.83 (95% CI: 1.08–3.09, P¼0.024). The
median value was used as a cutoff point for HER2, HER3 and
HER4. A significant association between HER2 mRNA over-
expression and reduced OS was demonstrated (39 out of 134
deaths in HER2-positive vs 22 out of 134 deaths in HER2-negative
patients, log-rank P¼0.024) (Figure 2A2). The HR for death in
HER2-positive patients was 1.81 (95% CI: 1.07–3.05, P¼0.027). In
contrast, HER3 as well as HER4 mRNA expression had a
favourable prognostic value in terms of OS (HR¼0.56, 95% CI:
0.33–0.94, P¼0.028 and HR¼0.50, 95% CI: 0.29–0.86, P¼0.011,
respectively) (Figure 2A3 and A4). Among 134 HER3-positive
patients 23 deaths were recorded, whereas among 133 HER3
negative patients 37 deaths were observed (log-rank P¼0.026).
Similarly, among 130 HER4-positive patients 21 deaths were
observed vs 38 deaths among 130 HER4-negative patients (log-
rank P¼0.010). In multivariate analysis that included 260 patients,
EGFR, HER2, HER3, and the number of involved axillary lymph
nodes, all independently affected OS (Table 3).
With respect to DFS, elevated HER2 mRNA expression was
associated with shorter DFS (52 out of 134 relapses in HER2-
positive vs 35 out of 134 relapses in HER2-negative cases, log-rank
P¼0.026) (Figure 2B2). The corresponding HR for relapse in
HER2-positive patients was 1.62 (95% CI: 1.06–2.49, P¼0.027).
HER4 mRNA expression was associated with lower risk for relapse
(HR¼0.49, 95% CI: 0.31–0.76, P¼0.002). Among 130 HER4-
positive patients 30 relapses were recorded, whereas 54 relapses
were observed in 130 HER4-negative cases (log-rank P¼0.001)
(Figure 2B4). In multivariate analysis (N¼260), HER4 and the
number of involved axillary nodes retained their prognostic
significance for DFS (Table 3).
Prognostic value of HER family members co-expression
Regarding the prognostic significance of specific co-expression
patterns of all four HER family receptors, we found that the
combination of low EGFR, low HER2, high HER3, and high HER4
mRNA expression was associated with significantly longer OS
compared not only with the combination of high EGFR, high
HER2, low HER3, and low HER4 mRNA expression (Po0.001), but
also compared with all other possible co-expression profiles
(P¼0.050). Similar findings were demonstrated for DFS
(P¼0.0021 and P¼0.031, respectively).
Patients with both EGFR and HER2 elevated expression had
significantly worse OS compared with those with either EGFR or
HER2 increased mRNA expression (P¼0.031), but DFS was not
significantly worse (P¼0.164).
Predictive value of HER family mRNA expression
The interaction between mRNA expression of HER2 and the
addition of paclitaxel was not significant for OS (P¼0.778). The
HR for death in paclitaxel containing chemotherapy (E-T-CMF)
among HER2-positive patients was 1.12 (95% CI: 0.60–2.11). With
respect to the DFS, the interaction was also non-significant
(P¼0.976). Among HER2-positive cases the HR for recurrence
of the paclitaxel containing treatment (E-T-CMF) was 1.05 (95%
CI: 0.61–1.81) (Figure 3). In the subgroup of ER-positive patients,
the interaction of HER2 mRNA expression and paclitaxel was still
non-significant (P¼0.952 and P¼0.860 for OS and DFS,
respectively). Similarly, the interaction of HER2 mRNA expression
and paclitaxel was not found to be significant in the subgroup of
ER-negative patients (P¼0.408 for OS and P¼0.654 for DFS).
In addition, mRNA expression of EGFR, HER3 and HER4 was not
predictive for benefit from adjuvant treatment with paclitaxel,
neither for OS nor for DFS (data not shown).
DISCUSSION
In this study, we used kinetic RT–PCR to analyse the transcrip-
tional profiling of the HER family receptor genes, in a
comparatively large series of high-risk (predominantly T2–3,
node-positive) early breast cancer patients, with a considerably
long follow-up of 8 years. Our analysis included gene transcription
assessment of all four HER family members. The majority of the
clinicopathological studies have focused on protein expression
and/or gene amplification of individual HER family receptors.
Consequently, the clinical outcome of breast cancer patients with
regard to HER family expression as a whole panel remains largely
unidentified. In addition, only a small number of trials have
evaluated HER family receptors at the mRNA level.
In our patient cohort, the overall concordance between
kRT–PCR and IHC/FISH for the determination of HER2 status
was good (74%). Our data confirm previous studies demonstrating
a substantial agreement between the results of HER2 status
evaluation at the mRNA and protein levels (Ginestier et al, 2004;
Gjerdrum et al, 2004; Vinatzer et al, 2005). A recent study that
compared four different methods of assessment of HER2 status
found a good correlation between RT–PCR and IHC, with an
overall concordance that varied from 82 to 93% (Ginestier et al,
2004). In another study that assessed HER2 status at the DNA,
mRNA and protein levels, the concordance of the RT–PCR with
the HercepTest was 86.4% (Vinatzer et al, 2005). Using the 75th
percentile as a threshold in our exploratory analysis, the
concordance between the two methods was higher (87%).
However, the prognostic ability of HER2 mRNA expression was
lost, suggesting that the increase in the cutoff point is likely to miss
the effect of lower, but potentially biologically important mRNA
levels of HER2. With the use of the median value as a threshold
and considering the IHC/FISH as the standard technique for HER2
assessment, the kRT–PCR assay was associated with a high level of
sensitivity (92%) and satisfactory specificity (67%). The majority
of HER2-positive tumours by IHC/FISH were also categorised as
HER2 positive by kRT–PCR (92%). However, among cases
showing strong protein expression in IHC, 8% displayed low
mRNA expression. This observation may be related either to
increased mRNA degradation in FFPE tumour blocks or to
accumulation of the protein product, due to aberrant catabolism.
Our findings suggest that kRT–PCR is an alternative method for
evaluating HER family receptors in FFPE breast tumours.
However, routine methods of histological fixation and tissue
processing could potentially damage or destroy RNA. In addition,
dilution of tumour genomic material by nucleic acids from non-
neoplastic tissue components is also a potential source of
imprecision (Gjerdrum et al, 2004). Furthermore, the required
equipment for kRT–PCR is not available in all histopathology
laboratories and is quite expensive.
The mRNA expression levels of HER3 and HER4 receptors were
positively correlated to each other and negatively correlated to
EGFR, in complete agreement with previously reported data
(Knowlden et al, 1998; Pawlowski et al, 2000; Bieche et al, 2003). In
addition, we demonstrated a positive association between HER2
and HER3 mRNA expression. A similar correlation was described
earlier, both at the mRNA and protein level (Bieche et al, 2003;
Witton et al, 2003; Sassen et al, 2008). It has been suggested that
the HER2/HER3 heterodimer constitutes the most mitogenic dimer
in the HER family (Citri et al, 2003). HER2 does not bind to
phosphatidylinositol 3-kinase (PI3K) and this function is directly
mediated through the HER3 receptor (Prigent and Gullick, 1994).
With respect to the relationships with the clinicopathological
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Figure 2 (A1)O S( P¼0.022) and B1. DFS (P¼0.076) for patients with EGFR mRNA expression o75th percentile (N¼200, blue line) and X75th
percentile (N¼67, red line). (A2)O S( P¼0.024) and B2. DFS (P¼0.026) for patients with HER2 mRNA expression omedian (N¼134, blue line) and
Xmedian (N¼134, red line). (A3)O S( P¼0.026) and B3. DFS (P¼0.135) for patients with HER3 mRNA expression omedian (N¼133, blue line) and
Xmedian (N¼134, red line). (A4)O S( P¼0.010) and B4. DFS (P¼0.001) for patients with HER4 mRNA expression omedian (N¼130, blue line)
and Xmedian (N¼130, red line).
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sparameters, our findings are in accordance with previous studies
evaluating the expression of HER family members in breast cancer,
either at the mRNA or the protein level.
In the prognostic analyses, we found a shorter OS in patients
with increased EGFR mRNA expression, using the 75th percentile
as a cutoff point. In addition, the prognostic significance of EGFR
for OS was maintained in the multivariate analysis. EGFR is
generally considered to be a negative prognostic factor in breast
cancer (Pawlowski et al, 2000; Tsutsui et al, 2002; Witton et al,
2003; Tzaida et al, 2007), but up to now, no definitive association
between EGFR expression and survival has been demonstrated.
The role of EGFR in HER2-mediated cellular transformation is not
fully elucidated. Experiments have provided some evidence for a
synergistic interaction of these receptors in cellular transformation
and induction of mammary tumours (DiGiovanna et al, 1998).
Moreover, interactions between EGFR and HER2 with respect to
the prognosis of breast cancer patients have been reported
(DiGiovanna et al, 2005). Similarly, in our study, patients with
both EGFR and HER2 mRNA overexpression had significantly
worse OS when compared to those with either EGFR or HER2
overexpression.
With regard to HER2, we confirmed its negative prognostic
significance in terms of OS and DFS. Moreover, HER2 retained its
prognostic value for OS in the multivariate analysis. Previous
studies investigating the prognostic value of HER2 using real-time
RT–PCR showed that this technique is clinically as useful in the
assessment of HER2 status as the current standard methods,
yielding comparable prognostic information (Vinatzer et al, 2005).
A recent study (Bergqvist et al, 2007) used quantitative real-time
PCR (Q-PCR) and RNA expression profiles (RNA-EP) to evaluate
HER2 status in relation to clinical outcome in breast cancer
patients. Analyses of relapse-free survival and OS on the basis of 5
and 10 years follow-up indicated that, in contrast to IHC/
chromogenic in situ hybridisation, both Q-PCR and RNA-EP
analyses yielded significant results after 10 years of follow-up.
These findings suggest that both Q-PCR and RNA-EP are of
similar, or even superior, prognostic value compared with the
current standard techniques.
The prognostic value of HER3 remains up to now unclear and
the available data are contradictory. A number of studies
evaluating HER family receptors have indicated a negative
prognostic value of HER3 in breast cancer patients (Bieche et al,
2003; Witton et al, 2003; Sassen et al, 2008). In contrast, our
present study showed a positive association between HER3 mRNA
expression and OS. Moreover, in the multivariate analysis HER3
maintained its prognostic value for OS. Other studies support the
positive prognostic ability of HER3 as well (Quinn et al, 1994;
Pawlowski et al, 2000; Lee et al, 2007). It has also been shown that
a naturally occurring secreted form of the human HER3 receptor is
a potent negative regulator of neuregulin-stimulated HER family
receptor activation (Lee et al, 2001).
Regarding the prognostic significance of HER4, a positive
association of HER4 mRNA expression with both OS and DFS
was shown. Furthermore, HER4 retained its prognostic power
for DFS in the multivariate analysis. Other studies have also
supported the favourable prognostic role of HER4 in breast cancer
both at the mRNA and the protein level (Pawlowski et al, 2000; Suo
et al, 2002; Witton et al, 2003). This positive effect is most likely
associated with an inhibitory effect on growth and differentiation
signalling. In cell line experiments, when HER2-positive cancer
cells were transfected to overexpress HER4, a reduction in
proliferation and an increase in apoptosis was observed (Sartor
et al, 2001). More recent studies have further increased our
knowledge regarding HER4-associated apoptosis (Naresh et al,
2006).
With respect to the prognostic power of the combined
expression profile of all four HER family receptors, we found that
the combination of low EGFR, low HER2, high HER3, and high
HER4 mRNA expression was associated with a significantly longer
OS and DFS, compared to any other combination. This finding
suggests that it is the co-expression pattern, rather than the
expression of individual family members, that should be taken into
account when evaluating the prognosis of the patients and making
individualised therapeutic decisions. Moreover, it has been
demonstrated that binding of specific ligands to the extracellular
domain allows for receptor homo- or heterodimerisation resulting
in activation of the cytoplasmatic catalytic function, which
leads to receptor autophosphorylation. This autophosphorylation
triggers a complex series of signal transduction pathways, such
as phosphatidylinositol 3-kinase-Akt, Ras-Raf-MEK-mitogen-
activated protein kinase-dependent pathway, PLC–PKC, and
JAK/STAT. These pathways affect essential tumorigenic processes,
such as proliferation, differentiation, migration, inhibition of
apoptosis, and enhanced survival. Therefore, apart from the
co-expression of the receptors, the expression of ligands, as well as
the cross-talk on different levels among the signal transduction
pathways, might also be important.
In this study, we also investigated the predictive ability of the
gene transcription of the HER family receptors in tumours of high-
risk breast cancer patients. The patients had participated in the
randomised HE10/97 trial evaluating the effect of anthracycline-
based dose-dense sequential adjuvant chemotherapy, with or
without paclitaxel (Fountzilas et al, 2005). Moreover, long-term
follow-up was available. Patient characteristics were well balanced
between the two arms with the exception of grade, a difference also
observed in the prospective clinical trial (Fountzilas et al, 2005).
The unbalance concerning histological grade is an important issue,
as it may have an impact on the results. However, since a
multivariate analysis was performed, including both grade and
Table 3 Multivariate analysis (N¼260)
OS DFS
HR 95% CI P-value HR 95% CI P-value
EGFR
o75th percentile 1 — — 1 — —
X75th percentile 1.71 1.00–2.93 0.050 1.52 0.95–2.44 0.079
HER2
oMedian 1 — —
XMedian 1.84 1.07–3.17 0.027
HER3
oMedian 1 — —
XMedian 0.53 0.30–0.91 0.021
HER4
oMedian 1 — —
XMedian 0.58 0.36–0.93 0.022
Number of nodes
0–3 1 — — 1 — —
X4 2.42 1.08–5.34 0.032 2.70 1.38–5.28 0.004
Grade
I–II 1 — —
III-Undifferentiated 1.52 0.96–2.41 0.071
Adjuvant hormonotherapy
No 1 — — 1 — —
Yes 0.48 0.23–0.99 0.50 0.52 0.27–0.99 0.046
Group of randomisation
E-T-CMF 1 — — 1 — —
E-CMF 0.85 0.51–1.41 0.526 0.93 0.60–1.45 0.928
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srandomisation arm, all presented results take into account this
unbalance.
To the best of our knowledge, this is the first study evaluating
the effect of a taxane-containing regimen vs a non-taxane
treatment, according to HER2 status at the mRNA level. In the
HE10/97 clinical trial, the addition of paclitaxel had no influence in
DFS and OS. In our patient cohort, the interaction between HER2
mRNA expression in the tumours and the addition of paclitaxel
was not significant. In the entire HE10/97 trial, the hazard of death
was significantly reduced when patients with negative hormonal
receptor status were treated with paclitaxel. There is evidence that
ER positivity may represent a negative predictive factor for the
response to chemotherapy in breast cancer (Berry et al, 2006). In
our patient cohort, performing an exploratory analysis based
on ER status, no significant HER2/paclitaxel interaction was found
in either ER-positive or ER-negative patients. Therefore, no
predictive ability of HER2 mRNA expression for paclitaxel was
established in our study.
Recently, investigators from the CALGB 9344 randomised
adjuvant trial (Henderson et al, 2003) reported that patients with
HER2-positive tumours derived significant benefit from the
addition of paclitaxel to a doxorubicin–cyclophosphamide regi-
men regardless of ER status, whereas there was no additional
benefit in HER2-negative, ER-positive cases (Hayes et al, 2007). In
another randomised study comparing docetaxel-based (TAC) with
non-docetaxel-containing adjuvant chemotherapy, the observed
reduction in the risk for relapse in patients treated with TAC, did
not seem to be driven by HER2 status (Martin et al, 2005). A recent
study, investigating the predictive power of HER2 protein
overexpression assessed by IHC in patients who were part of the
HE10/97 trial, did not find predictive ability of HER2 for treatment
with paclitaxel (Kostopoulos et al, 2006). However, a meta-analysis
(Dhesy-Thind et al, 2008) including the above three trials
(Martin et al, 2005; Kostopoulos et al, 2006; Hayes et al, 2007)
demonstrated a significant interaction in terms of DFS. Patients
with HER2-positive tumours derived greater benefit from the
taxane, but there was a significant benefit for both groups. Up to
date, clinical results regarding the interaction of HER2 receptor
status and the sensitivity to taxanes are contradictory. Further-
more, preclinical data suggest that HER2 overexpression may
contribute to paclitaxel resistance in breast cancer cells (Yu et al,
1996; Ueno et al, 1997). Consequently, cautious interpretation of
the available data is required and additional studies are warranted
to clarify these relationships.
Regarding EGFR, a recently published study reported that EGFR
protein expression, assessed by IHC, was a negative prognostic
marker in the absence of paclitaxel in patients with high-risk
operable breast cancer (Tzaida et al, 2007). In our study, no
significant interaction between EGFR mRNA level and treatment
with paclitaxel was found for either OS or DFS. Furthermore, no
significant interaction of HER3 and HER4 mRNA expression with
the treatment group was demonstrated.
In conclusion, the present study suggests that EGFR as well as
HER2 mRNA overexpression are prognostic factors of worse
clinical outcome in high-risk operable breast cancer patients,
whereas HER3 and HER4 mRNA overexpression are both
associated with a better prognosis. The combined expression
profile of the HER family receptors, and not the isolated
HER2 < median value
HER2 ≥ median value HER2 ≥ median value
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Figure 3 OS (A1 and A2) and DFS (B1 and B2) for patients treated with (red line) or without (blue line) paclitaxel, according to HER2 mRNA
expression. A1 and B1 (HER2 omedian): 55 (41%) E-T-CMF and 79 (59%) E-CMF-treated patients. A2 and B2 (HER2Xmedian): 62 (46%) E-T-CMF and
72 (54%) E-CMF-treated patients.
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sexpression of individual members, is likely to be more important
when assessing the prognosis of the patients. Furthermore, on the
basis of our findings, HER2 gene transcription does not predict
greater sensitivity to paclitaxel-based adjuvant chemotherapy. In
addition, kinetic RT–PCR represents a valid alternative method
for detection and quantification of HER family receptor gene
expression in FFPE breast tumour tissues.
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